{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
aminosalicylic acid
to a specific field?
Status:
Investigational
Source:
INN:oxiniacic acid [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Oxiniacic Acid is a nicotinic acid derivative, that shows potent hypolipidemic activity.
Status:
Investigational
Source:
NCT00739739: Phase 2 Interventional Completed Interstitial Cystitis
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT00169559: Phase 2 Interventional Completed Dyslipidaemias
(2003)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
GW 590735 is a selective and potent agonist of peroxisome proliferator-activated receptor alpha (PPARα), a ligand-activated transcription factor that plays a key role in lipid homeostasis. Activation of PPARα results in increased clearance of triglyceride (TG) rich very low-density lipoprotein. GW 590735 was in phase II clinical trial for the treatment of dyslipidemia, but that study was discontinued.
Class (Stereo):
CHEMICAL (ACHIRAL)
Besunide was studied as a diuretic agent.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Piriprost (U-60, 257) is a structural analog of prostaglandin I2 (PGI2) with low IP receptor-mediated activity. It inhibits 5-LO (5-lipoxygenase). Piriprost inhibits the release of histamine and leukotrienes, implicating its role in inflammation and allergic responses. However, it was shown, that piriprost did not influence the airway responses after allergen in asthma. Nevertheless, even more, the drug was irritant to the respiratory tract than was placebo.
Status:
Investigational
Source:
INN:yohimbic acid [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Yohimbinic acid, also known as yohimbic acid is an indole alkaloid, which was isolated from dried roots of Rauwolfia serpentina. Yohimbinic acid is a potent inhibitor of a human DNA Topoisomerase I and can inhibit cancer cells growth.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
OPINIAZIDE (also known as saluzid) was used for the treatment of meningeal tuberculosis in adults and in children. Information about the current use of this drug is not available.
Status:
Investigational
Source:
NCT00151736: Phase 2 Interventional Terminated Chronic Lymphocytic Leukemia
(2004)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
R-etodolac (SDX-101) is the non-cyclooxygenase 2-inhibiting R-enantiomer of the non-steroid anti-inflammatory drug etodolac (1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid). The absolute configuration of the enantiomer is R-(-)-etodolac. R-etodolac specifically bound retinoid X receptor (RXRalpha), inhibited RXRalpha transcriptional activity, and induced its degradation by a ubiquitin and proteasome-dependent pathway. In addition R-etodolac can disrupt the beta-catenin signaling pathway. R-etodolac exerts antineoplastic properties. R-etodolac was in phase 2 studies for the treatment of hematologic malignancies however development was discontinued.
Status:
Investigational
Source:
NCT00597818: Phase 2 Interventional Completed NSAID-induced Gastroduodenal Injury
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Cobristone is a locally acting chloride channel activator that works to stimulate and protect the mucosal barrier function. Cobristone is being developed by the Sucampo Pharmaceuticals, Inc. for the prevention of oral mucositis and for the treatment of non-erosive reflux disease (NERD), a major subtype of gastroesophageal reflux disease. The development of the drug was terminated after phase 2 clinical trials failed to meet its primary endpoints.
Status:
Investigational
Source:
INN:salclobuzic acid [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Salclobuzate sodium was developed as an oral absorption promoter. This compound had to “chaperone” poorly permeable payloads across the intestine. Information about the current use of this compound is not available.
